Evidence map›Paper›PMID 39299239›Full record

ArticleAmerican journal of human genetics2024

Somatic mutations in arteriovenous malformations in hereditary hemorrhagic telangiectasia support a bi-allelic two-hit mutation mechanism of pathogenesis.

Evon DeBose-Scarlett, Andrew K Ressler, Carol J Gallione, Gonzalo Sapisochin Cantis, Cassi Friday, Shantel Weinsheimer, Katharina Schimmel, Edda Spiekerkoetter, Helen Kim, James R Gossage and 2 more

Erratum issuedAbstract read
In one paragraph

Article in American journal of human genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Gene-Specific Endothelial Programs Drive AVM Pathogenesis inArteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Case report: Novel homozygousFrontiers in genetics · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Evon DeBose-ScarlettMolecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Andrew K ResslerMolecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Carol J GallioneMolecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Gonzalo Sapisochin CantisAbdominal Transplant and HPB Surgical Oncology, Toronto General Hospital and Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON PMB-11-175, Canada.
Cassi FridayCure HHT, Monkton, MD 21111, USA.
Shantel WeinsheimerDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94110, USA.
Katharina SchimmelDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, Stanford, CA 94305, USA.
Edda SpiekerkoetterDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, Stanford, CA 94305, USA.
Helen KimDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94110, USA.
James R GossageDepartment of Medicine, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.
Marie E FaughnanDivision of Respirology, Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada; Toronto HHT Centre, St. Michael's Hospital and Li Ka Shing Knowledge Institute, Toronto, ON M5B 1W8, Canada.
Douglas A MarchukMolecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: douglas.marchuk@duke.edu.

Funding

VCRC Administration UnitU54NS065705 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KIM, HELEN · 2009 to 2023
$20.8M
Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regressionR01HL169787 · NHLBI · STANFORD UNIVERSITY · PI Edda Frauke Spiekerkoetter · 2023 to 2026
$2.8M
NHLBI NIH HHS R01 HL169787NINDS NIH HHS U54 NS065705
6 · The paper itself

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder of vascular malformations characterized by mucocutaneous telangiectases and arteriovenous malformations (AVMs) in internal organs. HHT is caused by inheritance of a loss of function mutation in one of three genes. Although individuals with HHT are haploinsufficient for one of these genes throughout their entire body, rather than exhibiting a systemic vascular phenotype, vascular malformations occur as focal lesions in discrete anatomic locations. The inconsistency between genotype and phenotype has provoked debate over whether haploinsufficiency or a different mechanism gives rise to the vascular malformations. We previously showed that HHT-associated skin telangiectases develop by a two-hit mutation mechanism in an HHT gene. However, somatic mutations were identified in only half of the telangiectases, raising the question whether a second-hit somatic mutation is a necessary (required) event in HHT pathogenesis. Here, we show that another mechanism for the second hit is loss of heterozygosity across the chromosome bearing the germline mutation. Secondly, we investigate the two-hit mutation mechanism for internal organ AVMs, the source of much of the morbidity of HHT. Here, we identified somatic molecular genetic events in eight liver telangiectases, including point mutations and a loss of heterozygosity event. We also identified somatic mutations in one pulmonary AVM and two brain AVMs, confirming that mucocutaneous and internal organ vascular malformations undergo the same molecular mechanisms. Together, these data argue that bi-allelic loss of function in an HHT gene is a required event in the pathogenesis of HHT-associated vascular malformations.

Indexed as

AllelesArteriovenous MalformationsMutationTelangiectasia, Hereditary HemorrhagicActivin Receptors, Type IIAdultFemaleGerm-Line MutationHumansLoss of HeterozygosityMaleMiddle AgedPhenotypeActivin Receptors, Type IIACVRL1 protein, humanloss of heterozygositysomatic mutationvascular malformation

Identifiers

PMID39299239
PMCPMC11480799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.